Mounjaro is not approved for use in children. For more information about the use of Trulicity in children, talk with your child’s doctor. The table below shows dosages of Trulicity and Mounjaro ...

The table below provides a comparison of Trulicity and Mounjaro: Mounjaro is a dual-acting GLP-1/GIP receptor agonist. It is designed to mimic the effects of two natural hormones involved in blood ...

Mounjaro (tirzepatide) led to greater weight loss and better glucose control than high doses of Trulicity (dulaglutide), according to a study published April 4 in Annals of Internal Medicine.

Eli Lilly’s incretin-based diabetes meds Trulicity (dulaglutide) and Mounjaro have run scarce in the U.S., according to the FDA’s online drug shortage database. For the dual GIP/GLP-1 med ...

On December 15, 2022 the FDA listed Mounjaro as one of almost 200 drugs in a supply shortage, joining Wegovy, Ozempic (semaglutide) and Trulicity (dulaglutide), Eli Lilly’s other diabetes drug ...

The additions come as Lilly earlier this week flagged challenges to meet demand for the two drugs, especially as it makes six dosage forms of Mounjaro and four of Trulicity. "We do expect to see ...